A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
This study has been completed.
Information provided by (Responsible Party):
AVEO Pharmaceuticals, Inc.
First received: August 31, 2009
Last updated: April 11, 2012
Last verified: April 2012
A pharmacodynamic study to evaluate the effect of AV-299 on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastases.
To evaluate safety and tolerability of AV-299 administered IV in subjects with advanced solid tumors who have liver metastases.
Malignant Solid Tumour
||Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases (P05670)
Primary Outcome Measures:
- To evaluate the effect of AV-299 (formerly SCH 900105) on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastases [ Time Frame: Screening Cycle 1: Day 1, Day 3-4: Cycle 2: Day 1 Cycle 3: Day 8-14 ] [ Designated as safety issue: Yes ]
Peripheral blood analysis, liver tissue analysis, and PET
- To evaluate safety and tolerability of AV-299 (formerly SCH 900105) administered IV in subjects with advanced solid tumors who have liver metastases [ Time Frame: DLTs assessed during first 4 weeks of treatment. ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- To evaluate the PK of AV-299 (formerly SCH 900105) in subjects with advanced solid tumors who have liver metastases [ Time Frame: Cycle 1: Day 1, Day 3-4 Cycle 2: Day 1 Cycle 3: Day 1, Day 8-14 ] [ Designated as safety issue: No ]
- To study the preliminary antineoplastic activity of AV-299 (formerly SCH 900105) in subjects with advanced solid tumors who have liver metastases [ Time Frame: Subjects will undergo disease assessment at screening (within 4 weeks prior to first dose of study drug), the Cycle 3 Day 8-14 visit, and approximately every 6 weeks thereafter. ] [ Designated as safety issue: No ]
- To investigate the effect of AV-299 (formerly SCH 900105) on gene expression patterns in peripheral blood mononuclear cells and liver biopsies in subjects with advanced solid tumors who have liver metastases [ Time Frame: Cycle 1: Day 1, Day 3-4 Cycle 3: Day 8-14: ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||March 2011 (Final data collection date for primary outcome measure)
Experimental: AV-299 administered IV (monotherapy)
Subjects will be enrolled sequentially and treated with AV-299 (formerly SCH 900105) in dose escalating cohorts. Accrual to the next cohort will occur only if <= 1 out of 6 subjects experiences a dose-limiting toxicity (DLT) during the first 2 cycles. If >= 2 subjects in the same dose cohort experience a DLT during the first 2 cycles, dose-escalation will be terminated.
AV-299 will be given as an intravenous infusion in dose-escalating doses of 2, 10, and 20 mg/kg once every 2 weeks.
Other Name: Ficlatuzumab, Formerly SCH900105
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Ability to give written informed consent and be able to adhere to dose and visit schedules.
- Diagnosis of an advanced colorectal, breast, gastric/esophageal or pancreatic cancer with liver metastases that are amenable to biopsy.
- Histological or cytological evidence of malignancy.
- Advanced metastatic colorectal, breast, gastric/esophageal or pancreatic cancer that has recurred or progressed following standard therapy or failed standard therapy; or for which no standard therapy currently exists, or for which subject is not a candidate for, or is unwilling to undergo standard therapy.
Note: Additional tumor histologies may be eligible based on available HGF/c-Met pathway data and approval by the Sponsor.
- Disease that is currently not amenable to curative surgical intervention.
- Male or female and ≥ 18 years of age.
- ECOG performance status of 0-1.
- Measurable p-Met by immunohistochemistry in archived or otherwise available tumor sample.
- Female subjects of childbearing potential must have negative pregnancy test within 5 days prior to first dose of study drug.
- Female subjects of childbearing potential and male subjects whose sexual partners are of childbearing potential must agree to abstain from sexual intercourse or to use an effective method of contraception during the study and for 60 days after the last dose of AV-299 (formerly SCH 900105). Examples of effective methods of contraception include oral contraceptives or double barrier methods such as condom plus spermicide or condom plus diaphragm.
- Adequate hematologic function as evidenced by Hg ≥ 9g/dL, WBC ≥ 3000 per mm3, ANC ≥ 1500 per mm3 and platelet count ≥ 100,000 per mm3.
- Adequate hepatic function as evidenced by a serum bilirubin level ≤ 1.5 × ULN (except with known Gilbert's Syndrome) and with serum AST/ALT levels ≤ 5 × ULN.
- Adequate renal function as evidenced by a serum creatinine level ≤ 1.5 × ULN or a calculated creatinine clearance > 60 mL/min.
- Adequate coagulation function as evidenced by PTT ≤ 1.5 × ULN and INR ≤ 1.5 × ULN.
- Recovery from the effects of any prior surgery, radiotherapy, or systemic antineoplastic therapy.
- Subjects with abnormal liver function tests (LFTs) who have not been screened for Hepatitis B or C within the past 6 months prior to study enrollment, will need to be screened for Hepatitis B and C and can only be enrolled if the screening is negative.
- Women who are breast-feeding, pregnant, or intend to become pregnant.
- Hematologic malignancies.
- Any of the following within 6 months prior to administration of study drug:
- Myocardial infarction (MI), severe/unstable angina pectoris, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or seizure disorder.
- Serious/symptomatic active infection, or infection requiring antibiotics, within 14 days prior to first dose of study drug.
- Persistent, unresolved CTCAE v3.0 Grade 2 or higher drug-related toxicity (except alopecia, erectile dysfunction, hot flashes, decreased libido, and Grade 2 sensory peripheral neuropathy) associated with previous treatment.
- Inadequate recovery from any prior surgical procedure or major surgical procedure performed within 4 weeks prior to administration of first dose of study drug.
- Any other medical or psychiatric condition that, in the opinion of the investigator, might interfere with the subject's participation in the trial or interfere with the interpretation of trial results.
- Known Human Immunodeficiency Virus (HIV) infection or a known HIV-related malignancy.
- Known active hepatitis B or C.
- Known hypersensitivity to any of the components of SCH 900105.
- Known bleeding diathesis.
- Radiotherapy within 3 weeks prior to first study drug administration.
- Inability to comply with the protocol requirements, including inability to undergo liver biopsies.
- Participation in any other clinical trials involving therapeutic agents.
- Any medications prohibited in the study.
- Active alcohol or illicit drug abuse.
- Stem cell/bone marrow transplant within 6 months of first dose of study drug.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00969410
|Investigational Site 1
|Barcelona, Spain |
AVEO Pharmaceuticals, Inc.
||Shefali Agarwal, MD
||AVEO Pharmaceuticals, Inc.
No publications provided
||AVEO Pharmaceuticals, Inc.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 31, 2009
||April 11, 2012
||Spain: Agencia Española de Medicamentos y Productos Sanitarios
Keywords provided by AVEO Pharmaceuticals, Inc.:
Digestive system neoplasms
Neoplasms by site
Digestive system diseases
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on August 28, 2014
Neoplasms, Second Primary
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases